$HRMY
Harmony Biosciences Holdings Inc

2021 Q4 Form 10-Q Financial Statement

#000155837021015173 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $91.21M $80.73M $45.61M
YoY Change 62.04% 77.01%
Cost Of Revenue $17.82M $14.60M $7.890M
YoY Change 79.61% 85.1%
Gross Profit $73.40M $66.13M $37.72M
YoY Change 58.28% 75.32%
Gross Profit Margin 80.47% 81.91% 82.7%
Selling, General & Admin $37.31M $33.34M $23.11M
YoY Change 20.41% 44.26% -9.26%
% of Gross Profit 50.84% 50.41% 61.27%
Research & Development $7.451M $11.74M $4.230M
YoY Change -2.22% 177.52% -2.44%
% of Gross Profit 10.15% 17.75% 11.21%
Depreciation & Amortization $4.760M $4.672M $1.970M
YoY Change 8.68% 137.16%
% of Gross Profit 6.49% 7.07% 5.22%
Operating Expenses $44.77M $45.08M $27.34M
YoY Change 15.94% 64.87% -8.27%
Operating Profit $28.63M $21.05M $10.38M
YoY Change 268.96% 102.82% -134.83%
Interest Expense -$4.187M -$5.429M -$6.946M
YoY Change -47.47% -21.84% 231.55%
% of Operating Profit -14.62% -25.79% -66.92%
Other Income/Expense, Net $31.00K -$1.525M
YoY Change
Pretax Income $24.48M -$10.52M $1.909M
YoY Change -11754.76% -651.18% -105.98%
Income Tax $1.761M -$902.0K $0.00
% Of Pretax Income 7.2% 0.0%
Net Earnings $22.71M -$9.620M $1.909M
YoY Change -10916.19% -603.93% -105.98%
Net Earnings / Revenue 24.9% -11.92% 4.19%
Basic Earnings Per Share -$0.17 -$0.14
Diluted Earnings Per Share $375.5K -$0.17 -$0.14
COMMON SHARES
Basic Shares Outstanding 58.47M 57.72M 30.21M
Diluted Shares Outstanding 57.72M 30.21M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $234.3M $189.7M $221.7M
YoY Change 2.5% -14.43%
Cash & Equivalents $234.3M $189.7M $221.7M
Short-Term Investments
Other Short-Term Assets $3.218M $3.183M $5.625M
YoY Change 147.16% -43.41%
Inventory $4.432M $4.805M $2.311M
Prepaid Expenses $7.637M $9.793M $4.240M
Receivables $34.84M $33.21M $16.33M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $284.4M $240.7M $250.2M
YoY Change 8.2% -3.82%
LONG-TERM ASSETS
Property, Plant & Equipment $820.0K $937.0K $1.038M
YoY Change -12.58% -9.73%
Goodwill
YoY Change
Intangibles $143.9M $148.6M $66.63M
YoY Change -11.35% 122.98%
Long-Term Investments
YoY Change
Other Assets $3.515M $152.0K $1.418M
YoY Change 2212.5% -89.28%
Total Long-Term Assets $149.0M $150.4M $69.83M
YoY Change -9.25% 115.38%
TOTAL ASSETS
Total Short-Term Assets $284.4M $240.7M $250.2M
Total Long-Term Assets $149.0M $150.4M $69.83M
Total Assets $433.4M $391.1M $320.1M
YoY Change 1.49% 22.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.001M $4.179M $9.347M
YoY Change -60.84% -55.29%
Accrued Expenses $40.25M $34.22M $17.20M
YoY Change -67.2% 98.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.000M $2.000M
YoY Change
Total Short-Term Liabilities $53.78M $47.62M $31.79M
YoY Change -60.03% 49.8%
LONG-TERM LIABILITIES
Long-Term Debt $190.0M $190.1M $192.9M
YoY Change -2.2% -1.47%
Other Long-Term Liabilities $3.177M $1.382M $900.0K
YoY Change 187.51% 53.56%
Total Long-Term Liabilities $193.2M $191.5M $193.8M
YoY Change -1.12% -1.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.78M $47.62M $31.79M
Total Long-Term Liabilities $193.2M $191.5M $193.8M
Total Liabilities $246.9M $239.1M $225.5M
YoY Change -25.15% 6.02%
SHAREHOLDERS EQUITY
Retained Earnings -$453.6M -$476.3M
YoY Change -7.09%
Common Stock $640.1M $628.3M $582.5M
YoY Change 9.35% 7.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $186.5M $152.0M $94.55M
YoY Change
Total Liabilities & Shareholders Equity $433.4M $391.1M $320.1M
YoY Change 1.49% 22.18%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income $22.71M -$9.620M $1.909M
YoY Change -10916.19% -603.93% -105.98%
Depreciation, Depletion And Amortization $4.760M $4.672M $1.970M
YoY Change 8.68% 137.16%
Cash From Operating Activities $37.53M $30.42M $8.840M
YoY Change 273.83% 244.16%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$93.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 -$93.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $135.4M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.072M -313.0K 136.6M
YoY Change -709.66% -100.23%
NET CHANGE
Cash From Operating Activities 37.53M 30.42M 8.840M
Cash From Investing Activities 0.000 -93.00K 0.000
Cash From Financing Activities 7.072M -313.0K 136.6M
Net Change In Cash 44.61M 30.02M 145.5M
YoY Change 548.33% -79.36%
FREE CASH FLOW
Cash From Operating Activities $37.53M $30.42M $8.840M
Capital Expenditures $0.00 -$93.00K $0.00
Free Cash Flow $37.53M $30.52M $8.840M
YoY Change 273.83% 245.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001802665
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58414546
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56890569
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1217
CY2020Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1217
CY2020Q3 hrmy Preferred Stock Conversion Ratio
PreferredStockConversionRatio
0.1217
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39450
dei Entity Registrant Name
EntityRegistrantName
HARMONY BIOSCIENCES HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2279923
dei Entity Address Address Line1
EntityAddressAddressLine1
630 W.
dei Entity Address Address Line2
EntityAddressAddressLine2
Germantown Pike
dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 215
dei Entity Address City Or Town
EntityAddressCityOrTown
Plymouth Meeting
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19462
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
539-9800
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 value per share
dei Trading Symbol
TradingSymbol
HRMY
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58471519
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
189704000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228631000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
33206000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
22176000
CY2021Q3 us-gaap Inventory Net
InventoryNet
4805000
CY2020Q4 us-gaap Inventory Net
InventoryNet
3823000
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9793000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6959000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
3183000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1302000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
240691000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
262891000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
937000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
938000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
148562000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
162343000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
152000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
152000
CY2021Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
150401000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
164183000
CY2021Q3 us-gaap Assets
Assets
391092000
CY2020Q4 us-gaap Assets
Assets
427074000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4179000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2556000
CY2021Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
6785000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
8942000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34223000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
122727000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
436000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
314000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
47623000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
134539000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
190069000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
194250000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1382000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1105000
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
191451000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
195355000
CY2021Q3 us-gaap Liabilities
Liabilities
239074000
CY2020Q4 us-gaap Liabilities
Liabilities
329894000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58414546
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56890569
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
628329000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
585374000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-476312000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-488195000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
152018000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
97180000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
391092000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
427074000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80732000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45609000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
214227000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
103454000
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14604000
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7890000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
37701000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
17820000
CY2021Q3 us-gaap Gross Profit
GrossProfit
66128000
CY2020Q3 us-gaap Gross Profit
GrossProfit
37719000
us-gaap Gross Profit
GrossProfit
176526000
us-gaap Gross Profit
GrossProfit
85634000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11739000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4230000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22916000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11829000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16480000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12601000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
49009000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
38297000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16856000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10508000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
45704000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26280000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
45075000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
27339000
us-gaap Operating Expenses
OperatingExpenses
117629000
us-gaap Operating Expenses
OperatingExpenses
76406000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
21053000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
10380000
us-gaap Operating Income Loss
OperatingIncomeLoss
58897000
us-gaap Operating Income Loss
OperatingIncomeLoss
9228000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-63640000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-26146000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-26146000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-22639000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1525000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3071000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-5429000
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-6946000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-19783000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-20254000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10522000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1909000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
12953000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36736000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-902000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1070000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9620000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
1909000
us-gaap Net Income Loss
NetIncomeLoss
11883000
us-gaap Net Income Loss
NetIncomeLoss
-36736000
CY2020Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6013000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
26904000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9620000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4104000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
11883000
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.15
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.15
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57722163
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30212959
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57188101
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15324362
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57722163
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30212959
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58776158
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15324362
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
97180000
us-gaap Net Income Loss
NetIncomeLoss
11883000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29700000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1794000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11461000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
152018000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
126551000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9620000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29700000
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
167000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
17000
CY2020Q3 hrmy Temporary Equity Share Converted To Permanent Equity
TemporaryEquityShareConvertedToPermanentEquity
-318510205
CY2020Q3 hrmy Temporary Equity Value Converted To Permanent Equity
TemporaryEquityValueConvertedToPermanentEquity
-444715000
CY2020Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
444716000
CY2020Q3 hrmy Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
5468000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1073000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
94549000
CY2020Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
318510205
CY2020Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
434009000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-483362000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
1909000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
135435000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1134000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4253000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
152018000
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
318510205
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
411275000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-422862000
us-gaap Net Income Loss
NetIncomeLoss
-36736000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
135435000
hrmy Temporary Equity Share Converted To Permanent Equity
TemporaryEquityShareConvertedToPermanentEquity
-318510205
hrmy Temporary Equity Value Converted To Permanent Equity
TemporaryEquityValueConvertedToPermanentEquity
-444715000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
444716000
hrmy Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
5468000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
283000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1870000
CY2020Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
17000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
94549000
us-gaap Profit Loss
ProfitLoss
11883000
us-gaap Profit Loss
ProfitLoss
-36736000
us-gaap Depreciation
Depreciation
299000
us-gaap Depreciation
Depreciation
294000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
13781000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5560000
us-gaap Share Based Compensation
ShareBasedCompensation
11461000
us-gaap Share Based Compensation
ShareBasedCompensation
1870000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
261000
hrmy Stock Appreciation Rights Market Adjustment
StockAppreciationRightsMarketAdjustment
396000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3109000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1820000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1020000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-26146000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-22639000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11030000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12071000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
982000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1223000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3715000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8169000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
476000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1623000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2987000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
9461000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
7738000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
16000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
30000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
61024000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13032000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
298000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
hrmy Cash Paid For Milestones
CashPaidForMilestones
100000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-100298000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
147628000
hrmy Payment Of Initial Public Offering Issuance Costs
PaymentOfInitialPublicOfferingIssuanceCosts
11021000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30000000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
300000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
200000000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
200000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
9147000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
5804000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
200000000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
102538000
hrmy Payments Of Extinguishment Of Debt Exit Fees
PaymentsOfExtinguishmentOfDebtExitFees
-22000000
hrmy Payments Of Extinguishment Of Debt Exit Fees
PaymentsOfExtinguishmentOfDebtExitFees
-18047000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1794000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
283000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
167000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
17000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
347000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
210317000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38927000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
197283000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229381000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25207000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190454000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
222490000
us-gaap Interest Paid Net
InterestPaidNet
15997000
us-gaap Interest Paid Net
InterestPaidNet
19549000
hrmy Warrant Financing
WarrantFinancing
2359000
hrmy Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
5468000
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
410239
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-8.215
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-476312000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-488195000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
189704000
CY2020Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
135435000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosures in the unaudited condensed consolidated financial statements, including the notes thereto, and elsewhere in this report. Uncertainties related to the magnitude and duration of COVID-19, the extent to which it will impact our estimated future financial results, worldwide macroeconomic conditions including interest rates, employment rates, consumer spending and health insurance coverage, the speed of the anticipated recovery and governmental and business reactions to the pandemic have increased the complexity of developing these estimates, including the carrying amounts of long-lived assets, and the intangible asset. Actual results may differ significantly from our estimates, including as a result of COVID-19.</p>
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
189704000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228631000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
750000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
190454000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
229381000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 36pt;"><b style="font-style:normal;font-weight:bold;">Concentrations of Risk</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Substantially all of the Company’s cash and money market funds are held with a single financial institution. Due to its size, the Company believes this financial institution represents minimal credit risk. Deposits in this institution may exceed the amount of insurance provided on such deposits by the Federal Deposit Insurance Corporation for U.S. institutions. The Company has not experienced any losses on its deposits of cash and cash equivalents. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also subject to credit risk from its trade receivables related to its product sales. The Company monitors its exposure within accounts receivable and records a reserve against uncollectible accounts receivable as necessary. The Company extends credit to specialty pharmaceutical distribution companies within the United States. Customer creditworthiness is monitored and collateral is not required. Historically, the Company has not experienced credit losses on its accounts receivable. As of September 30, 2021, three customers accounted for 100% of gross accounts receivable; Caremark LLC (“CVS Caremark”), which accounted for 36% of gross accounts receivable; PANTHERx Specialty Pharmacy LLC (“Pantherx”), which accounted for 34% of gross accounts receivable; and Accredo Health Group, Inc. (“Accredo”), which accounted for 30% of gross accounts receivable. As of December 31, 2020, three customers accounted for 100% of gross accounts receivable; CVS Caremark, which accounted for 44% of gross accounts receivable; Pantherx, which accounted for 23% of gross accounts receivable; and Accredo, which accounted for 33% of gross accounts receivable.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the nine months ended September 30, 2021, three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 36% of gross product revenues; Pantherx accounted for 36% of gross product revenues; and Accredo accounted for 28% of gross product revenues. For the nine months ended September 30, 2020 three customers accounted for 100% of gross product revenues; CVS Caremark accounted for 40% of gross product revenues; Pantherx accounted for 34% of gross product revenues; and Accredo accounted for 26% of gross product revenues.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company depends on a single source supplier for its product and active pharmaceutical ingredient.</p>
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2660000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
396000
CY2021Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
2424000
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1798000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
941000
CY2021Q3 us-gaap Inventory Gross
InventoryGross
5245000
CY2020Q4 us-gaap Inventory Gross
InventoryGross
3997000
CY2021Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1023000
CY2021Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
440000
CY2020Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
174000
CY2021Q3 us-gaap Inventory Net
InventoryNet
4805000
CY2020Q4 us-gaap Inventory Net
InventoryNet
3823000
CY2019Q4 hrmy License Agreement Milestone Payments Paid
LicenseAgreementMilestonePaymentsPaid
75000000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P8Y
CY2021Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P9Y
us-gaap Finite Lived Intangible Assets Remaining Amortization Period1
FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
P8Y
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4573000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1867000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
13781000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5560000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
4643000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
18570000
CY2021Q3 hrmy Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
69639000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
148562000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
18570000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
18570000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
18570000
CY2021Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
175000000
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
175000000
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
26438000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
12657000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
148562000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
162343000
CY2019Q3 hrmy License Agreement Milestone Payments Paid
LicenseAgreementMilestonePaymentsPaid
2000000
CY2019Q4 hrmy License Agreement Milestone Payments Paid
LicenseAgreementMilestonePaymentsPaid
75000000
CY2019Q3 hrmy License Agreement Additional Milestone Payments Due
LicenseAgreementAdditionalMilestonePaymentsDue
102000000
CY2019Q3 hrmy Licensing Agreement Milestone Fees
LicensingAgreementMilestoneFees
2000000
CY2021Q1 hrmy License Agreement Milestone Payments Due
LicenseAgreementMilestonePaymentsDue
100000000
CY2021Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
13202000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9006000
CY2021Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
13202000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9006000
CY2021Q3 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
15067000
CY2020Q4 hrmy Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
7803000
CY2021Q3 us-gaap Interest Payable Current
InterestPayableCurrent
2125000
CY2021Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
851000
CY2020Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1905000
CY2021Q3 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
790000
CY2020Q4 hrmy Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2186000
CY2021Q3 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1678000
CY2020Q4 hrmy Accrued Professional Fees Consulting And Other Services
AccruedProfessionalFeesConsultingAndOtherServices
1081000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
510000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
746000
CY2020Q4 hrmy Accrued Milestone Payment Current
AccruedMilestonePaymentCurrent
100000000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34223000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
122727000
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
200000000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
200000000
CY2020Q4 hrmy Debt Instrument Exit Fees
DebtInstrumentExitFees
14000000
CY2021Q3 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
7931000
CY2020Q4 hrmy Unamortized Debt Discount Associated With Exit Fee Debt Financing Costs And Discount With Warrant Financing
UnamortizedDebtDiscountAssociatedWithExitFeeDebtFinancingCostsAndDiscountWithWarrantFinancing
19750000
CY2021Q3 us-gaap Long Term Debt
LongTermDebt
192069000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
194250000
CY2021Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2000000
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
190069000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
194250000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
500000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2000000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2000000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
20000000
CY2021Q3 hrmy Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
155500000
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
200000000
CY2021Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
5030000
CY2020Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
6655000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
18122000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
19549000
CY2021Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
459000
CY2020Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
340000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1820000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1020000
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
5489000
CY2020Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
6995000
us-gaap Interest Expense Debt
InterestExpenseDebt
19942000
us-gaap Interest Expense Debt
InterestExpenseDebt
20569000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
420000
us-gaap Operating Lease Expense
OperatingLeaseExpense
773000
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
161000
us-gaap Operating Lease Expense
OperatingLeaseExpense
516000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
134000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
875000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
892000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
334000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2235000
CY2019 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2020Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-8.215
CY2020Q3 us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
1-for-8.215
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote for each share
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5210832
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.66
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M17D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1391803
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
35.02
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
268569
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
357617
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
23.66
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5976449
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.76
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M10D
hrmy Securities Outstanding Included In Computation Of Utilizing Treasury Stock Method
SecuritiesOutstandingIncludedInComputationOfUtilizingTreasuryStockMethod
1588057
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6085742
hrmy Share Based Compensation Expense Income
ShareBasedCompensationExpenseIncome
-2000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.6000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5500
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9580
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0066
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0119
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0032
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0056
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.52
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.06
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1330000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11722000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2266000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
63450000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y9M18D
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4664000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9620000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
1909000
us-gaap Net Income Loss
NetIncomeLoss
11883000
us-gaap Net Income Loss
NetIncomeLoss
-36736000
CY2020Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6013000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
26904000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9620000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4104000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
11883000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-63640000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.15
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.15
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57722163
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30212959
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57188101
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5461704
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15324362
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57722163
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30212959
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58776158
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15324362
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4680651
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5461704
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1525000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3109000
CY2021Q3 hrmy Related Party Transaction Payment For Advisory Fee
RelatedPartyTransactionPaymentForAdvisoryFee
2300000

Files In Submission

Name View Source Status
0001558370-21-015173-index-headers.html Edgar Link pending
0001558370-21-015173-index.html Edgar Link pending
0001558370-21-015173.txt Edgar Link pending
0001558370-21-015173-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hrmy-20210930.xsd Edgar Link pending
hrmy-20210930x10q.htm Edgar Link pending
hrmy-20210930x10q_htm.xml Edgar Link completed
hrmy-20210930xex31d1.htm Edgar Link pending
hrmy-20210930xex31d2.htm Edgar Link pending
hrmy-20210930xex32d1.htm Edgar Link pending
hrmy-20210930xex32d2.htm Edgar Link pending
hrmy-20210930_cal.xml Edgar Link unprocessable
hrmy-20210930_def.xml Edgar Link unprocessable
hrmy-20210930_lab.xml Edgar Link unprocessable
hrmy-20210930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending